Latest News

Filters close
16-Dec-2014 2:00 PM EST
Study Published in the New England Journal of Medicine Finds Intra-Arterial Treatment for Clot Removal Is More Effective at Treating Stroke Than Standard Medical Care
Stryker Neurovascular

Investigators found that using intra-arterial treatment to remove a stroke-causing blood clot in a large vessel supplying blood to the brain provides better outcomes than trying to dissolve the clot using a clot-busting drug (lytic) alone.

4-Aug-2014 11:00 AM EDT
Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits in Mouse Models of SMA
Roche

Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in a mouse model of Spinal Muscular Atrophy (SMA).

Released: 7-Feb-2014 9:00 AM EST
Survey Shows Majority of Americans Have Their Heart Health Facts Wrong
Cleveland Clinic

Despite the fact that heart disease is the leading cause of death for both men and women in the U.S., about three-quarters (74 percent) of Americans do not fear dying from it, according to a recent survey from Cleveland Clinic.

6-Jan-2014 12:00 PM EST
Roche Reports New Method for Efficiently Transporting Antibodies Across the Blood-Brain Barrier
Roche

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models. Roche Pharma Early Research and Development (pRED) scientists found that such enhanced transfer of antibodies through the BBB was associated with a marked improvement in amyloid reduction in the brain of a mouse model of Alzheimer’s disease.

   
Released: 15-Oct-2013 12:05 AM EDT
Baylor College of Medicine Researchers Find Community-based Weight Loss Intervention Yields Greater Weight Loss than Self-help Approach
Weight Watchers International, Inc.

A new randomized controlled trial conducted by Baylor College of Medicine researchers and published today as an Article in Press in The American Journal of Medicine finds that overweight and obese adults following a community-based weight loss intervention, namely Weight Watchers, lost significantly more weight than those who tried to lose weight on their own (10.1 lbs. vs. 1.3 lbs. at six months). Those in the Weight Watchers group were provided with three access routes – group meetings, mobile applications, and online tools – and further analysis found those who used all three access routes together lost the most weight.

Released: 17-Oct-2012 10:30 AM EDT
Pfizer Consumer Healthcare Responds to PHS II Findings with Statement and Centrum® Silver® Multivitamin B-Roll and Photo Assets
Ketchum PR, NYC

Pfizer Consumer Healthcare is very pleased that study investigators at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, chose Centrum® Silver® for the Physicians’ Health Study II. The Centrum® multivitamins’ quality, among other factors, led investigators to choose Centrum® Silver® for inclusion in the study. Centrum® Silver® multivitamins currently available in stores have since been updated and improved to reflect advances in nutritional science.

Released: 27-Sep-2011 8:50 AM EDT
American Association of Clinical Endocrinologists and Takeda Launch Diabetes Navigator Website
Takeda Pharmaceuticals North America

The American Association of Clinical Endocrinologists (AACE) and Takeda Pharmaceuticals North America Inc. (Takeda) have partnered to launch the Diabetes Navigator (http://DiabetesNavigator.AACE.com), a compendium capturing a selection of useful and reliable type 2 diabetes information available online for patients and caregivers.

Released: 23-Mar-2011 8:00 AM EDT
New Nationwide Survey Identifies Need for Increased Dialogue Between Gastroesophageal Reflux Disease or Frequent Heartburn Sufferers and Health Care Providers
Takeda Pharmaceuticals North America

According to findings from the new nationwide DISCUSS Survey, many people surveyed report that their gastroesophageal reflux disease (GERD) and/or persistent heartburn symptoms significantly disrupt their lives.

Released: 6-Apr-2010 11:30 AM EDT
CHEST Analysis: Blood Tests Demonstrate Superior Accuracy in Diagnosing Tuberculosis
Cellestis Limited

New data from a meta-analysis of existing literature published today in CHEST, the official journal of the American College of Chest Physicians, demonstrate that Interferon Gamma Release Assays (IGRAs) are superior to the previous standard in diagnostics, the 100+-year-old tuberculin skin test (TST), for detecting confirmed active TB disease.

Released: 5-Apr-2010 11:30 AM EDT
Qutenza (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available.

Released: 19-Oct-2009 9:00 AM EDT
ULORIC (febuxostat) Demonstrated EfficacyFor Management of Hyperuricemia in Patients with Gout
Takeda Pharmaceuticals North America

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment.

Released: 15-Oct-2009 9:00 AM EDT
Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met as Initial Therapy Compared to Either Component Alone
Takeda Pharmaceuticals North America

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of ≤7 percent compared to either component alone. Safety and tolerability of ACTOplus met therapy were evaluated by rate of drug discontinuation and treatment-emergent adverse events.

Released: 1-Jun-2009 2:15 PM EDT
IMPACT Study Showed Longer Valcyte (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
Roche

New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ("˜prophylaxis') with Valcyte (oral valganciclovir) significantly reduced the incidence of CMV disease by 56% in high-risk kidney transplant patients within the first year post-transplant.

Released: 16-Feb-2009 9:00 AM EST
FDA Approves ULORIC (Febuxostat) for Chronic Management of Hyperuricemia in Gout Patients
Takeda Pharmaceuticals North America

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout.

Released: 2-Feb-2009 9:00 AM EST
FDA Approves KAPIDEX (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
Takeda Pharmaceuticals North America

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

Released: 25-Nov-2008 9:00 AM EST
Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients with Gout
Ketchum PR, NYC

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of approval, with one panel member abstaining. The vote followed presentations by Takeda Global Research & Development Center, Inc., the FDA, and invited guest speakers. If approved in the United States by the FDA, febuxostat will be the first new treatment for the management of hyperuricemia associated with gout in more than 40 years.

Released: 9-Jun-2008 10:30 AM EDT
Phase 3 Results for Alogliptin
Takeda Global Research & Development

Results from five pivotal phase 3 studies of alogliptin, a highly selective DPP-4 inhibitor, were announced at the ADA 68th Scientific Sessions. Alogliptin administered once daily demonstrated statistically significant reductions in HbA1c versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications.

Released: 27-May-2008 12:30 PM EDT
AMITIZA (R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
Ketchum PR, NYC

Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA (R) (lubiprostone) 8 mcg capsules are now available by prescription in pharmacies across the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. AMITIZA 24 mcg capsules have been available by prescription to treat Chronic Idiopathic Constipation in adults since 2006.

Released: 19-May-2008 8:45 AM EDT
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
Ketchum PR, NYC

New study results indicated that treatment with AMITIZA (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists.

Released: 31-Mar-2008 11:30 AM EDT
ACTOS (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
Ketchum PR, NYC

New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

Released: 11-Jan-2008 1:00 PM EST
"Full Metal Jacket" and Bodybuilding Drugs for the Heart
Montefiore Health System

Montefiore Medical Center recently became the first hospital in the Northeast to implant a HeartNet cardiac restriction device in a patient, part of a study aimed at patients with advanced heart failure. The device is applied in a minimimally invasive procedure and through its unique properties the mesh "jacket" decreases wall stress and promotes reverse remodelling of an enlarged heart.

Released: 4-Jan-2008 9:00 AM EST
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Takeda Global Research & Development

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

Released: 4-Dec-2007 8:50 AM EST
Ketchum PR, NYC

A new study presented today showed that ramelteon did not exacerbate respiratory depressant effects in patients (40 years and older) with moderate to severe chronic obstructive pulmonary disease (COPD), as measured by oxygenation or abnormal breathing events relative to placebo. Results of this double-blind, placebo-controlled trial were presented at the 53rd International Respiratory Congress of the American Association for Respiratory Care.

Released: 6-Nov-2007 9:45 AM EST
Increased HDL with ACTOS Slowed Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
Takeda Pharmaceuticals North America

Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes. What and When Additional results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), will be presented as an oral session at the American Heart Association Scientific Sessions 2007 being held November 4 through 7, 2007 in Orlando, Florida. Results revealed that reduced progression of carotid intima-media thickness (CIMT), the thickness of the inner lining of a patient's carotid, with ACTOS was associated with increased HDL cholesterol and decreased insulin levels when compared to glimepiride. An increase in CIMT is an indicator of atherosclerosis, a condition that leads to reduced or blocked blood flow and is a surrogate marker for the risk of heart attack and stroke.

Released: 19-Sep-2007 7:45 AM EDT
Takeda Pharmaceuticals North America

Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes.

Released: 11-Sep-2007 4:55 PM EDT
Takeda Statement on ACTOS (pioglitazone HCl) Meta-Analysis Published in JAMA
Ketchum PR, NYC

Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy.

Released: 31-Aug-2007 1:00 PM EDT
Worldsleep 2007: Ramelteon Demonstrates Sustained Efficacy Over Six Months in Adults with Chronic Insomnia
Ketchum PR, NYC

Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2007. This large clinical study demonstrated that ramelteon was effective in reducing time to fall asleep for up to six months versus placebo in adult patients with chronic insomnia.

19-Jul-2007 8:50 AM EDT
Boehringer Ingelheim Launches RLS Initiative
Boehringer Ingelheim Pharmaceuticals

Restless legs syndrome (RLS) remains a common, yet often undiagnosed, neurological sensorimotor disorder, despite many years of research and increased disease recognition. To help drive understanding and disease awareness among physicians and people with RLS, Boehringer Ingelheim Pharmaceuticals, Inc. has launched an initiative to educate about the symptoms, diagnosis and treatment of RLS.

Released: 12-Jul-2007 12:00 PM EDT
New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation
Ketchum PR, NYC

Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

Released: 25-Jun-2007 9:00 AM EDT
Ketchum PR, NYC

The first ever human data for Alogliptin, Takeda's investigational compound for Type 2 diabetes, being presented at the ADA annual meeting going on in Chicago, IL. Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.

Released: 25-Jun-2007 9:00 AM EDT
Ketchum PR, NYC

Multiple Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions regarding ACTOS, Takeda's treatment for Type 2 diabetes

Released: 22-May-2007 6:00 PM EDT
Ketchum PR, NYC

A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo. This study also demonstrated, as in previous studies, that patients treated with zolpidem did have impaired performances on these measures, as compared to placebo.

22-May-2007 3:00 PM EDT
Iloperidone Results Show Favorable Akathisia Profile
Vanda Pharmaceuticals

According to study results presented today at the 2007 American Psychiatric Association annual meeting, iloperidone, an investigational atypical antipsychotic, was shown to have a favorable akathisia profile. Akathisia "“ a debilitating sensation of restlessness that manifests as an inability to sit still "“ is a frequent side effect of antipsychotic medications.

Released: 21-May-2007 8:45 AM EDT
Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation
Ketchum PR, NYC

A new study demonstrated that the active ingredient in AMITIZA® (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).

Released: 7-May-2007 4:00 PM EDT
Roche

Interim results from a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept® (mycophenolate mofetil) were presented at the American Transplant Congress. This and other Spare the Nephron (STN) trials in kidney and liver transplant recipients examine ways to prevent rejection without damaging kidneys.

Released: 12-Mar-2007 9:50 AM EDT
Ketchum PR, NYC

Dr. Judith Reichman, a well-known women's health specialist, is giving women food for thought with "Straight Talk on Women's GI Health" (www.GIStraightTalk.com), a new campaign about digestive health.

Released: 13-Nov-2006 12:05 PM EST
Ketchum PR, NYC

Results demonstrated significant improvements on cardiovascular markers beyond glycemic control.

Released: 2-Nov-2006 3:55 PM EST
African-American Organ Donation Could Increase with One Step: Discussing Wishes with Family
Links, Incorporated

With more African Americans than ever on the waiting list for an organ transplant, a new survey finds that half (49 percent) of African Americans want their organs donated upon death, and most (80 percent) consider saving lives the top reason for becoming an organ donor. But more than half of them (56 percent) have not talked to their families about it "“ a key step to becoming an organ donor.

Released: 24-Oct-2006 5:05 PM EDT
AMS Announces Program to Provide Advanced Clinical Training in Neurogastroenterology
American Motility Society

American Motility Society Announces Program to Provide Advanced Clinical Training in Neurogastroenterology and GI Motility at Centers of Excellence - Program Made Possible Through Grant to American Motility Society from Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

Released: 23-Oct-2006 9:25 AM EDT
AMITIZA™ (lubiprostone) Phase III Constipation Trial Results
Takeda Pharmaceuticals North America

In recent studies, AMITIZAâ„¢ (lubiprostone) demonstrated improvements in relief of symptoms associated with irritable bowel syndrome with constipation (IBS-C), such as abdominal bloating and discomfort.

Released: 23-Oct-2006 9:20 AM EDT
Study Demonstrated AMITIZA™ (lubiprostone) Showed Efficacy
Takeda Pharmaceuticals North America

Additional safety study finds AMITIZA also provided improvements in symptoms of chronic idiopathic constipation in long-term use

Released: 18-Oct-2006 2:10 PM EDT
Takeda Pharmaceuticals North America

HBO's ENTOURAGE Actress Debi Mazar leads a national campaign to help "Sleepless Moms" get rest.

Released: 14-Sep-2006 5:00 PM EDT
ACTOS (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes
Ketchum PR, NYC

Several abstracts presented today at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated that ACTOS® (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes.

Released: 5-Sep-2006 10:25 AM EDT
Ketchum PR, NYC

Results of new analyses found that ACTOS® (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the risk of recurrent stroke in high-risk patients with type 2 diabetes. The findings were presented today in a late-breaker session at the World Congress of Cardiology in Barcelona.

Released: 19-Jun-2006 10:00 AM EDT
ROZEREM™ (ramelteon) Shown to be Effective in a First-Night-Effect Model
Ketchum PR, NYC

Data presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies have shown that ROZEREMTM (ramelteon) reduced time to fall asleep with no evidence of next-day residual effects, including psychomotor and memory effects, in a first-night-effect model of transient insomnia. The results of this double-blind, randomized study were presented as a poster presentation.

Released: 13-Jun-2006 9:00 AM EDT
New Results from the Landmark PROactive Trial
Takeda Pharmaceuticals North America

New analyses from the landmark PROactive Study found that ACTOS® (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the occurrence of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes.

Released: 9-Jun-2006 4:10 PM EDT
ACTOS® (pioglitazone HCl) To Be Studied In New Trial
Takeda Pharmaceuticals North America

Researchers today at the American Diabetes Association (ADA) 66th Annual Scientific Sessions presented data showing the relationship between baseline characteristics and cardiac risk factors in patients enrolled in a new clinical trial called CHICAGO.

Released: 23-May-2006 1:00 PM EDT
Novartis Pharmaceuticals

Data from a head-to-head clinical study looking at the effects of two prescription medications used to treat overactive bladder (OAB) showed that treatment with Enablex® (darifenacin) did not result in impaired memory function in healthy adults age 60 and older . In contrast, treatment with Ditropan XL® (oxybutynin extended-release or ER), the other medication evaluated in the study, caused significant memory deterioration.

Released: 22-May-2006 10:20 AM EDT
Ketchum PR, NYC

A new study found that AMITIZAâ„¢ (lubiprostone) may help relieve the symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive disease specialists.


Showing results

150 of 162

close
0.30297